Do you know where I can find a copy of the liquidation judgment or a document confirming that the action has been delisted ? I live in France and my stock market intermediary needs documents to close my position and recover my capital loss. Thanks for your help.
You know these SOB's never get what they deserve... they benefit while others suffer. So what IYO is the next step? As for me, I would love to find a effective way of targeted retribution to the many scumbuckets who've not only royally fuked me, but so many other good, honest people... I have a long list. I would love to endorse and support such an effort. I would even consider being a leading force in that endeavor. So how do you see it?
Yup. They should all be jailed. Frank lorenzo was calling investors with the doctor on a conference call on daily base promising more development into the company with the purchase of preferred share. God they are all scammer.
Victor must be one of the greediest SOB around... look he was/is working his scam in Dubai because being a jew he must have great affection and love for the Arab world, lol. Greedy SOB ended up sucking investors into his scam, then walks away with everything scot free. Justice is not being served.... Find Victor and Hang the SOB!
Corporate america. I meet them in person too.
How is it that they are not tracked down and sued for knowing they were scamming people with false information. I lost money and I know a lot of people lost a lot of money.
No. They scammed all the money. FRANK LORENZO...STEVEN VICTOR..ANA RODES all scammers. They call you personally for you to invest in their company and runs off . Fine con artist...cheers.
1.00 next week
I think it is non reporting, Company sucked the shareholders dry
Cause the system is messed up
How in hell is this guy in business still after all the money he owes other investors?
Meh, his twitter is silent. Regen Websites updated a lil bit. Intellicell not so much.
Guilt precedes a guilty conscience. So, absolutely NOT
do you have a guilty conscience
Aimed at someone in particular?
What a shame to think what that money could actually be doing in a real stock!!! That's what kills me about it. Well I will never ever get involved with these subs again! I might as well just stop coming to IHUB too..
I won't admit to the actual number, but I'll tell you it's significantly more than your loss....by a lot.
Unfortunately, I don't think this is his first failure based on other lawsuits filed. I don't know all the facts, so I'll just say he got all of us on this one. IMO
15k I’m ashamed to admit
I would love to hear from anyone on their big losses and by how much!
This and another company no longer showing information on my Scottrade account. Finally some closure in this shit show. Don’t worry, Steven Victor is doing quite well with newly remodeled medical facility. Likely paid for with our money.
Hopefully the company will do the filings some times in the near future? All IMO
My Broker at Fidelity told me that as a pinkie they really do not have to file until they feel like it which really does not do them much good with investors!!!
I show the same thing in my account, not sure why or how or what will happen but its there. LOL Maybe one day we can wake up and make a few dollars on this deal.
Any news about SVFC filings?
I have shares through Scottrade and Fidelity, as Scottrade doesn't always fill my trades when price is lower than their requirements and Fidelity will fill all orders, as I have shares in both companies I checked with both companies and SVFC is still trading as I show on my Scottrade site!!!
Just notified that my Scottrade has just merged with T D AMERITRADE, don't
care for TD Ameritrade so will probably transfer over to Fidelity!
A motion was filed in the EU patent system to transfer the pending patent to "stromacell." Yet Regen is still borrowing intellicells technology as per the dermatology website
issued and outstanding as of November 19, 2014
an increase of 4,238,984,241
from the below
as of October 9, 2014
Common Stock from Ten Billion (10,000,000,000) shares of Common Stock to Two Hundred Fifty Billion (250,000,000,000) shares of Common Stock and (b) the Company’s preferred stock, par value $0.01 per share, from One Million (1,000,000) shares of preferred stock to Twenty-Five Million (25,000,000) shares of preferred stock
an increase of 1,299,077,468 between the above & below link
1) Holders of some of our promissory notes which are now in default could, if they were to successfully enforce those notes in a law suit, levy on our assets and have them sold to satisfy our obligations on the notes.
2) Part of our debt held by promissory note holders has been assumed by Redwood Management, LLC. However, our bridge notes and our convertible promissory notes held by some of our promissory note holders are in default, and we are not in a position to repay them. We intend to use the proceeds of a future offering to pay off such notes. Holders of those notes could if they choose to sue on those notes, and if they were successful in their lawsuits they could levy on our assets and have those assets sold to satisfy the amounts we owe them.
3) As of May 9, 2014, we had 228 holders of record of our common stock and 2,230,314,377 shares of common stock issued and
I will gladly let the investing public decide as
during this time Victor & Anna sold $1.5M worth of notes/shares this was also happening
TOTAL STOCKHOLDERS' DEFICIT (21,167,614) March 31, 2014 (9,849,067) December 31, 2013
NET LOSS $ (13,004,773) $ (1,058,459)
Number of shares of common stock issued and outstanding as of June 18, 2014 is 2,355,075,373.
Accumulated deficit (61,908,223) March 31, 2014 (48,903,450) December 31, 2013
Number of shares of common stock issued and outstanding as of June 18, 2014 is 2,355,075,373.
The number of outstanding shares of the Registrant’s Common Stock, $0.0001 par value, at May 9, 2014 was 2,230,314,377.
Dominion Capital Debenture
On March 24, 2014, Ironridge Global sold the TCA Note to Dominion Capital under the security settlement agreement executed between the Company and Dominion Capital, and the Company issued a convertible debenture to Dominion Capital in the amount of $746,092 (the “Dominion Debenture”). The $746,092 principal balance included the original TCA Note of $500,000, accrued interest and pre-payment penalties of $246,092.
The Dominion Capital Debenture matures on March 24, 2015 and accrues interest at an annual rate equal to 7.5%. At any time, and at its sole option, Dominion Capital can to convert a portion or all amounts of principal and interest due and outstanding under the Dominion Debenture into shares of common stock at a price equal to 48.5% of the average of the three lowest prices per share of reported trades (not on the same day) of the common stock on the OTC Markets or on the exchange which the common stock is then listed as quoted by Bloomberg, LP during the 20 trading days preceding the conversion date.
As of March 31, 2014, the Dominion Debenture had a principal balance of $746,092, and accrued interest of $1,088.
Quote:was only Victor & Anna were cashing in over $1.5M while also causing 31,720,856 shares to enter the market FACT
Part of our debt held by promissory note holders has been assumed by Redwood Management, LLC.
the above was installed & can only be removed or edited by BigBadWolf & NO data/info may be placed above it as per admin Ms. Linda's private message to ALL MOD's
Publication in The American Journal ofMedicine showing regenerative results of cardiac function with SVFC's patented technology
INTELLICELL BIOSCIENCES, INC.
About IntelliCell BioSciences, Inc.
IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC). VFC is also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. VFC type cells are in research projects and in clinical trials around the world.
IntelliCell was formed to take a leading role and harmonize the interests of all the stakeholder communities in the rapidly expanding regenerative medicine field. IntelliCell is fully committed to an ethical and supportive role in providing the tools to physicians and patients to fight some of the most serious disease conditions with very high levels of unmet clinical needs.
The VFC cells that are being processed by IntelliCell are known as autologous cells. That is the donor of cells and the recipient of the cells are the same person. IntelliCell is unique as it does not use any chemicals or biological agents such as collagenese in its proprietary and patent pending process. The Company has developed a novel ultrasound process to assist the laboratory in the preparation of the VFC cells. In a process similar to the acquisition of autologous stem cells from bone marrow aspirate, the IntelliCell VFC cells are being given to physicians working in the field of regenerative medicine.
LATEST SHAREHOLDER LETTER
NEW YORK, NY--(Marketwired - Dec 10, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, provides shareholder update.
Dear Valued Shareholders,
On behalf of myself, the Board of Directors and the entire IntelliCell team, I would like to let you know that we are pleased with the growth initiatives that we have accomplished since our initial shareholder letter.
Now is an important and exciting time for IntelliCell Biosciences. We have continued to improve our competitive position in the regenerative medicine field and I believe we have never been stronger or better positioned for future growth. The worldwide regenerative medicine market is being driven by previously unseen treatments and procedures that are improving the quality of life of patients around the world and we firmly believe that we will emerge as one of the leaders in this industry.
The Company has been executing on our strategic plan and business priorities this year. We have made advancements in our technology and have filed patents around the world for our proprietary regenerative medical solutions. I am encouraged by the expanding market presence of IntelliCell Biosciences and the escalating acceptance of the Company's products and solutions within the medical, scientific and investment community. Additionally, we continue to work hard at improving our balance sheet and financial position, in order to have the necessary resources to take advantage of our growth opportunities. Because of all these accomplishments, I believe we are better positioned than ever for growth.
We have focused primarily on three strategic initiatives, Growth, Leverage, and Financial Strength, in order to improve the overall standing of the company.
Growth: We will continue to grow and supply our cellular product to physicians to treat their patients with clinical needs. We intend to be a major provider of minimally manipulated stromal vascular fraction cells SVFCs for autologous use to physicians and achieve exciting clinical results that improve the quality of life for their patients.
Leverage: We are leveraging our scale and best practices to create a cost-effect business model that increases our competitive advantage over our industry peers. Our intent is to open 3 additional facilities in 3 states in the next 12 months. Once the model is perfected, we will roll out additional facilities at a more aggressive pace. As the regenerative medical market expands, we intend to be the most recognized name in the industry.
Financial Strength: We have a goal of improving our balance sheet and income statement in order to deliver strong shareholder returns. Currently we are enacting a plan to remove all debt from our balance sheet. Going forward, it is our intent to use equity capital for the advancement of our company. Believing that IntelliCell Biosciences stock is undervalued, I will be converting a portion of my debt into shares and will continue this practice going forward. These measures will enable us to continue implementing our business and open new Cellular Labs in hospitals and ambulatory surgical centers that will significantly increase our revenues.
We are committed to advance the regenerative medicine field. This will enable us to become more productive, reliable and cost effective than ever before. IntelliCell's physician partners have informed us that we are well-aligned with their strategic intentions, and their clinical and business priorities. These are the key priorities that will ensure IntelliCell's future success.
As many of you know, our technology is new and cutting edge and requires acceptance by the marketplace and the regulators. We will remain aggressive in our efforts to overcome industry obstacles so that our medical solutions can serve as the industry standard. The Company has successfully developed advanced medical technologies, most notably its patented process of isolating SVFCs from adipose (fat) tissue using a mechanical technique, exclusive to the industry of regenerative medicine, now being used by physicians to treat patients with previously unmet clinical needs.
Management firmly believes that regenerative medicine is the future of medicine and we intend to aggressively expand our market footprint in order to solidify our position as the leader in the field. We would like to express our gratitude to our loyal global customer base and we are grateful to our shareholders for their continued support and ownership in our company. As CEO and Founder of IntelliCell, my paramount responsibility is to enhance shareholder value. I take immense pride in the success of this company to date and remain committed to delivering the best products and services possible to increase market presence in the future.
We at IntelliCell Biosciences are confident that our vision and goals will be achieved.
Dr. Steven Victor
Chief Executive Officer
IntelliCell Biosciences, Inc.
Link to the most recent FDA Inspection Form 483 issued on 06/06/2013 http://www.ipscell.com/wp-content/uploads/2013/08/Intellicell-483_2013.pdf
DD COMPILATION (January 30, 2014)